| 查看: 626 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
yaping221木虫 (正式写手)
|
[求助]
脂组学类翻译，谢谢！
|
|
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. |
回复此楼» 猜你喜欢
各位大神，目前国内有哪些比较好用的逆合成软件？
已经有14人回复
-
国社科系统bug了，是不是要放榜了？
已经有10人回复
-
现代”学阀”该如何界定
已经有9人回复
-
课题组招2027级博士 上海工程技术大学 激光智能制造方向
已经有4人回复
-
上海工程技术大学 激光智能制造课题组 2027级博士研究生招生
已经有3人回复
-
上海工程技术大学激光智能制造课题组｜2027级博士研究生招生公告
已经有11人回复
-
申博发邮件
已经有11人回复
-
我的奶奶
已经有3人回复
genhunter
至尊木虫 (著名写手)
- 翻译EPI: 387
- 应助: 259 (大学生)
- 金币: 9757.4
- 散金: 10
- 红花: 60
- 帖子: 2484
- 在线: 1793小时
- 虫号: 2558361
- 注册: 2013-07-22
- 专业: 肿瘤化学药物治疗
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. 在未来基于脂类组学和代谢组学的个性化医学可以加快对合适病人的选择，以及选对药物，用药时间和剂量的决定。最近, 更为有效的药物，包括能抑制前蛋白转化酶枯草溶菌素 9型（PCSK9）和炎症通路的单克隆抗体已经开发，用于改善冠状动脉疾病的治疗。 However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. 然而，在目前看来，这些新的靶向治疗比较昂贵，难以在所有冠状动脉疾病患者中广泛应用。因此，需要用灵敏的生物标志物去确定最合适新疗法以代谢和脂类生物标志物测定的的候选患者, 尤其是神经酰胺，未来有可能成为临床上有用的辅助诊断。 |
2楼2016-03-05 15:38:03